Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

Study:

Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezum II)

Rationale:

n/a

Purpose:

To evaluate the safety and efficacy of the Rezum System and assess its effect on urinary symptoms secondary to benign prostatic hyperplasia (BPH).

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Benign Prostatic Hyperplasia
Lower Urinary Tract Symptom
Device: Rezum System
Procedure: Rigid Cystoscopy
N/A

Verified by NxThera Inc December, 2013

Sponsored by: NxThera Inc
Information provided by: NxThera Inc
ClinicalTrials.gov identifier: NCT01912339

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Claus Roehrborn, MD., Principal Investigator
Kevin McVary, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site